On the evening of August 4th, Hanyu Pharmaceutical (300 199. SZ) announced that its application for clinical trial registration of HY3000 nasal spray in COVID-19 has been accepted by the State Administration of Pharmaceutical Products.
Hanyu Pharmaceutical said that HY3000 nasal spray is a new type of polypeptide membrane fusion inhibitor. By combining with COVID-19 spike protein HR 1, it can prevent the formation of six-helix bundle structure of virus and prevent the virus from infecting cells, thus achieving antiviral effect. The indication of this clinical trial is to prevent novel coronavirus (coronavirus pneumonia-19).